

Scandion Oncology – Notice Convening an Extraordinary General Meeting

The appointed liquidator hereby gives notice of an extraordinary general meeting in:

Scandion Oncology A/S (under frivillig likvidation)

CVR no. 38613391

(the "**Company**")

to be held on 6 October, 2026, at 11.00 am (CET), at HortenDahl Advokatpartnerselskab, Philip Heymans Alle 7, 2900 Hellerup, Denmark.

With the following agenda:

1. Election of chairman of the meeting
 - The appointed liquidator proposes that Diana Bojaj attorney-at-law, is elected chairman of the meeting.
2. Proposal to approve the final liquidation accounts
 - The appointed liquidator proposes that the final liquidation accounts (included as schedule 1) are approved.
3. Proposal to liquidate the Company with final effect
 - The appointed liquidator proposes that the company is liquidated with final effect.

Proposal to liquidate the Company with final effect

The liquidation process is now approaching its conclusion. As anticipated, and as set out in the final liquidation accounts attached as Schedule 1, there will be no proceeds available for distribution to shareholders.

In my capacity as liquidator, I would like to take this opportunity to say a final thank you to the shareholders who have supported the Company in its endeavors to revert cancer drug resistance.

Attendance and casting of votes at the general meeting

A shareholder's right to attend the general meeting and to vote on its shares is determined on the basis of the shares held by the shareholder at the date of registration.

The date of registration is 29 September 2026 ("**Date of Registration**").

Only shareholders in the Company as at the Date of Registration have the right to attend the general meeting and vote on their shares.

The shares held by each shareholder at the Date of Registration are calculated based on the registration of the number of shares held by the shareholder in the Company's register of shareholders as well as any notification of ownership received by the Company on or before the Date of Registration for the purpose of registration in the Company's register of shareholders, but which as of the Date of Registration had not yet been registered.

Any sale or purchase of shares in the Company taking place after the Date of Registration and until the date of the general meeting will not affect the voting rights at the general meeting.

Admission Card, Proxy and Postal Voting

In order to attend the general meeting, a shareholder must request an admission card no later than 4 October, 2026, 11.59 p.m. (CET). The request shall be made to the Company, e-mail: info@scandiononcology.com.

All shareholders are entitled to attend the general meeting by proxy. If a shareholder wishes to attend by proxy, the shareholder will need to request an admission card for the proxy holder as set out above and fill out a written and dated instrument of proxy. The proxy holder must be able to present the admission card and the written and dated instrument of proxy at the general meeting.

Proxies may be submitted in writing by using the written proxy form attached to this notice as schedule 2 and which can also be found on the Company's website www.scandiononcology.com. The Company requests that signed forms are sent to the Company by e-mail to: info@scandiononcology.com no later than 4 October, 2026 at 11.59 p.m. (CET). Proxies received after this date cannot be expected to have been received at the general meeting.

A shareholder can also choose to make use of postal vote instead of attending the general meeting in person.

Postal votes may be submitted in writing by using the postal vote form attached to this notice as schedule 2 and which also can be found on the Company's website www.scandiononcology.com. A completed and signed form must be received by the Company by e-mail to: info@scandiononcology.com no later than 4 October, 2026 at 11.59 p.m. (CET).

Postal votes received by the Company cannot be cancelled or revoked.

Nominee

To be entitled to participate in the general meeting, shareholders whose shares are registered in the name of a nominee must re-register their shares in their own names in the share register. Such registration must be duly effected in the share register or duly notified to the Company on the Date of Registration, and the shareholders must therefore advise their nominees well in advance of the general meeting.

Please note that a nominee is entitled to participate in the general meeting for the shares registered in the nominee's name. In such case, the nominee is responsible for acting only on the basis of explicit instruction from the actual owner(s) of the shares in question.

Schedules

Schedule 1: Draft final liquidation accounts

Schedule 2: Proxy and postal vote form

For further information please contact:

Appointed Liquidator, Johnny Stilou

E-mail: info@scandiononcology.com

September 21, 2026